[ad_1] Shares of Neuland Laboratories rallied over 9% on Friday, September 27 after the United States Food and Drug Administration’s (USFDA) approval of Bristol Myers Squibb’s (BMS) new schizophrenia drug, Cobenfy (also known as KarXT). According to market experts, Neuland Laboratories is likely to be one of the active pharmaceutical ingredient (API) suppliers for the […]